India approves its first dengue vaccine: Takeda’s QDENGA gets DCGI nod in major public health breakthrough

India has approved its first dengue vaccine as the DCGI grants clearance to Takeda's QDENGA. Here's everything you need to know about the vaccine, how it works, who can receive it, its global approvals, and what this landmark decision means for dengue prevention in India.

New Delhi: After decades of battling one of the world’s fastest-spreading mosquito-borne diseases with little more than vector control and supportive treatment, India has taken a landmark step in dengue prevention. Japanese pharmaceutical giant Takeda’s dengue vaccine, QDENGA, has received approval from India’s drug regulator, making it the country’s first approved vaccine against dengue.

The approval is particularly significant because India accounts for nearly one-third of the world’s dengue burden, while reported dengue cases in the country have increased 11-fold over the last 20 years, according to Takeda. With no widely deployed dengue vaccine available until now, the regulatory clearance opens the door for a new preventive tool alongside mosquito control measures and public awareness campaigns.

Historic first for India

Takeda Pharmaceutical announced on Monday that its dengue vaccine QDENGA (TAK-003) has been approved by India’s drug regulator, becoming the first dengue vaccine to receive regulatory approval in the country. The approval follows an extensive regulatory review, including Phase III clinical data generated in the Indian population and recommendations by the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO).

The development comes........

© News9Live